Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Algernon Pharmaceuticals ( (TSE:AGN) ) has provided an announcement.
Algernon Health Inc. plans to change its corporate name to Grey Matters Health Inc., aligning its brand with an expanding focus on Alzheimer’s disease diagnostics and brain health. The rebranding supports the rollout of NovaScan Neuroimaging Clinics across the U.S., with the first PET scanning clinic to be located at the HCA Florida University Hospital campus in Davie.
Concurrently, the company will implement a 10-for-1 consolidation of its Class A common shares, reducing the outstanding count from about 54.2 million to roughly 5.4 million, subject to Canadian Securities Exchange approval. The consolidation will also proportionally adjust preferred shares, warrants, stock options, and restricted share units, signaling a capital structure reset as the company pivots toward a clinic-based neuroimaging business model while retaining its drug development assets.
The most recent analyst rating on (TSE:AGN) stock is a Sell with a C$0.05 price target. To see the full list of analyst forecasts on Algernon Pharmaceuticals stock, see the TSE:AGN Stock Forecast page.
Spark’s Take on AGN Stock
According to Spark, TipRanks’ AI Analyst, AGN is a Neutral.
The score is primarily held back by very weak fundamentals (no revenue, continued losses, and ongoing cash burn), despite improvement in loss and burn rates and a debt-free balance sheet. Technicals show short-term strength but are overextended and still below longer-term trend levels. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on AGN stock, click here.
More about Algernon Pharmaceuticals
Algernon Health Inc., soon to be renamed Grey Matters Health Inc., is a Canadian healthcare company focused on brain-specific PET scanning services. It is building a network of U.S. neuroimaging clinics for early detection of Alzheimer’s disease and other dementias, as well as epilepsy, neuro-oncology conditions, and movement disorders such as Parkinson’s disease.
The company also maintains legacy drug development assets, including a program for Repirinast, a repurposed drug for chronic kidney disease, and intellectual property related to DMT for stroke and traumatic brain injury. Algernon retains a 20% stake in U.S.-based Seyltx Inc., which is advancing former Algernon asset Ifenprodil in chronic cough.
Average Trading Volume: 88,350
Technical Sentiment Signal: Sell
Current Market Cap: C$2.32M
Learn more about AGN stock on TipRanks’ Stock Analysis page.